BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19331801)

  • 21. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.
    Belo VA; Souza-Costa DC; Lana CM; Caputo FL; Marcaccini AM; Gerlach RF; Bastos MG; Tanus-Santos JE
    Clin Biochem; 2009 Jul; 42(10-11):984-90. PubMed ID: 19358835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension.
    Tayebjee MH; Karalis I; Nadar SK; Beevers DG; MacFadyen RJ; Lip GY
    Am J Hypertens; 2005 Mar; 18(3):325-9. PubMed ID: 15797648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Behavior of MMP-2, MMP-7, MMP-9, and Their Inhibitors TIMP-1 and TIMP-2 in Adenoma-Colorectal Cancer Sequence.
    Barabás L; Hritz I; István G; Tulassay Z; Herszényi L
    Dig Dis; 2021; 39(3):217-224. PubMed ID: 32961536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreases in plasma MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in uremic patients during hemodialysis.
    Lu LC; Yang CW; Hsieh WY; Chuang WH; Lin YC; Lin CS
    Clin Exp Nephrol; 2016 Dec; 20(6):934-942. PubMed ID: 26711243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents.
    Głowińska-Olszewska B; Urban M
    Metabolism; 2007 Jun; 56(6):799-805. PubMed ID: 17512313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis.
    Rysz J; Banach M; Stolarek RA; Mikhailidis DP; Cialkowska-Rysz A; Pokoca L; Piechota M; Baj Z
    Int Urol Nephrol; 2011 Jun; 43(2):491-8. PubMed ID: 19953348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipid Peroxidation, Protein Oxidation, Gelatinases, and Their Inhibitors in a Group of Adults with Obesity.
    Caimi G; Canino B; Montana M; Urso C; Calandrino V; Presti RL; Hopps E
    Horm Metab Res; 2019 Jun; 51(6):389-395. PubMed ID: 31075797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2.
    Tayebjee MH; Lip GY; Blann AD; Macfadyen RJ
    Thromb Res; 2005; 115(3):205-10. PubMed ID: 15617743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of MMP-2 and MMP-9 in resistance to drug therapy in patients with resistant hypertension.
    Lacerda L; Faria AP; Fontana V; Moreno H; Sandrim V
    Arq Bras Cardiol; 2015 Aug; 105(2):168-75. PubMed ID: 26039662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
    Lorenzl S; Buerger K; Hampel H; Beal MF
    Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C.
    Lichtinghagen R; Huegel O; Seifert T; Haberkorn CI; Michels D; Flemming P; Bahr M; Boeker KH
    Clin Chem; 2000 Feb; 46(2):183-92. PubMed ID: 10657374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Roles of matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase and hs-CRP in Kawasaki disease].
    Chen R; Zhang AR; Zhao XX; Li ZH
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Dec; 11(12):989-91. PubMed ID: 20113606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of hemodialysis on the plasma level of type IV collagenases and their inhibitors.
    Chou FP; Chu SC; Cheng MC; Yang SF; Cheung WN; Chiou HL; Hsieh YS
    Clin Biochem; 2002 Jul; 35(5):383-8. PubMed ID: 12270768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Plasma matrix metalloproteinases MMP-2 and MMP-9 and tissue inhibitors TIMP-1 and TIMP-2 in children treated for acute lymphoblastic leukemia].
    Krawczuk-Rybak M; Kuźmicz M; Mroczko B; Szmitkowski M
    Pol Merkur Lekarski; 2010 Jul; 29(169):14-8. PubMed ID: 20712241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated serum concentrations of metalloproteinases (MMP-2, MMP-9) and their inhibitors (TIMP-1, TIMP-2) in patients with Graves' orbitopathy.
    Kapelko-Słowik K; Słowik M; Szaliński M; Dybko J; Wołowiec D; Prajs I; Bohdanowicz-Pawlak A; Biernat M; Urbaniak-Kujda D
    Adv Clin Exp Med; 2018 Jan; 27(1):99-103. PubMed ID: 29521049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
    Klisho EV; Savenkova OV; Kondakova IV; Perel'muter VM; Choĭnzonov EL; Shishkin DA
    Vopr Onkol; 2007; 53(1):26-31. PubMed ID: 17649730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mercury exposure increases circulating net matrix metalloproteinase (MMP)-2 and MMP-9 activities.
    Jacob-Ferreira AL; Passos CJ; Jordão AA; Fillion M; Mergler D; Lemire M; Gerlach RF; Barbosa F; Tanus-Santos JE
    Basic Clin Pharmacol Toxicol; 2009 Oct; 105(4):281-8. PubMed ID: 19594729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
    J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies.
    Horstmann S; Kalb P; Koziol J; Gardner H; Wagner S
    Stroke; 2003 Sep; 34(9):2165-70. PubMed ID: 12907822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased plasma matrix metalloproteinase-2 (MMP-2), tissue inhibitor of proteinase-1 (TIMP-1), TIMP-2, and urine MMP-2 concentrations correlate with proteinuria in renal transplant recipients.
    Mazanowska O; Zabińska M; Kościelska-Kasprzak K; Kamińska D; Krajewska M; Banasik M; Madziarska K; Zmonarski SC; Chudoba P; Biecek P; Boratyńska M; Klinger M
    Transplant Proc; 2014 Oct; 46(8):2636-9. PubMed ID: 25380883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.